Clinical trials: Schizophrenia / Schizoaffective Disorder, open to volunteers
Schizophrenia Disorder, Schizoaffective Disorder
Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization
This study is a randomized controlled trial evaluating the impact of financial incentives on medication adherence among individuals with schizophrenia, schizoaffective disorder, or bipolar disorder and/or co-occurring substance…
- Conditions
- Schizophrenia Disorder, Schizoaffective Disorder, Bipolar Disorder (BD), Substance Use Disorder (SUD)
- Trial name
- NCT07130500
- Testing
- Financial incentives for adherence to long-acting injectable medication, Standard of care with monthly surveys
- Where
- 6 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Stanford University
Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP)
French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls
The goal of this study is to learn whether people living with severe psychiatric disorders can be grouped into more homogeneous subgroups, across usual diagnostic categories, based on two key dimensions: social withdrawal and…
- Conditions
- Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP), Bipolar Disorder (BD), Major Depressive Disorder (MDD
- Trial name
- FRENCH-MINDS (NCT07881016)
- Testing
- 3T Brain MRI, Biological Sampling, Clinical, Cognitive and Digital Assessments
- Where
- 17 sites in France
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fondation FondaMental
Severe Mental Illness, Bipolar Disorder
A Mobile App to Support Mood, Daily Routines and Medication Adherence in Adults With Severe Mental Illness
The goal of this clinical trial is to learn whether MoodSync, a mobile application for patients and their family caregivers, improves mood stability, medication adherence, daily functioning and early detection of relapse warning…
- Conditions
- Severe Mental Illness, Bipolar Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- MoodSync (NCT07879131)
- Testing
- MoodSync, Standard care
- Where
- Bahrain
- Volunteers
- 60 people
- Sponsor
- Alexandria University
Schizophrenia, Schizoaffective Disorder
NEURO-COGS: Neurometabolic Mechanisms of Cognitive Training in Schizophrenia
This study will examine brain metabolic and excitatory/inhibitory mechanisms related to cognitive and visual functioning in adults with schizophrenia and healthy control participants.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Cognitive Impairment, Visual Impairment
- Trial name
- NCT07788755
- Testing
- Perceptual Discrimination Training, Cognitive Control Training
- Where
- United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
SCHIZOPHRENIA 1 (Disorder), Schizoaffective Disorder
Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1
In Study 1, investigators will test the ability of each of the seven paradigms to differentiate between schizophrenia (SZ)/schizoaffective disorder (SZA) and matched healthy control subjects (HC) and to predict individual…
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Schizoaffective Disorder, Healthy Adult Participants
- Trial name
- CNTRACS (NCT07853807)
- Testing
- Motion Perception Task, Sine Wave Speech Task, Volatility Task
- Where
- 5 sites in United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder
Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia
In following guidelines for studying negative symptoms in schizophrenia, 60 patients aged 18-40, diagnosed with schizophrenia or schizoaffective disorder during the last ten years, will receive a combination of the iron chelator…
- Conditions
- Schizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder, Schizophrenia and Predominant Negative Symptoms
- Trial name
- IronMan (NCT07759895)
- Testing
- Deferiprone (DFP), N-Acetyl Cysteine (NAC)
- Where
- 2 sites in Israel
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Amit Lotan
Delusional Disorder, Brief Psychotic Disorder
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
FEEL-GOOD is a prospective multi-site single-blinded randomized controlled trial in young inpatients with acute early psychosis. Participants are randomized 1:1 to FEEL-GOOD plus treatment as usual (TAU) or TAU alone.
- Conditions
- Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder
- Trial name
- FEEL-GOOD (NCT07645443)
- Testing
- FEEL GOOD, Treatment as Usual (TAU)
- Where
- 8 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Stephanie Mehl
Early Psychosis, Psychosis
State Representation in Early Psychosis 2
This observational study will examine behavioral and electroencephalography measures related to state representation in individuals with early psychosis and healthy control participants.
- Conditions
- Early Psychosis, Psychosis, Schizophrenia, Bipolar Disorder With Psychosis
- Trial name
- STEP2 (NCT07834203)
- Where
- 2 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Schizophrenia, Schizoaffective Disorder
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT07105111
- Testing
- Valbenazine
- Where
- 19 sites in United States
- Volunteers
- 100 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia / Schizoaffective Disorder
tACS for Self-Other Boundary in Schizophrenia
This clinical trial investigates whether a non-invasive brain stimulation technique called transcranial alternating current stimulation (tACS) can improve the ability to distinguish between "self" and "others" in patients with…
- Trial name
- NCT07818668
- Testing
- Transcranial Alternating Current Stimulation (tACS)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chunyan Zhu
Schizophrenia / Schizoaffective Disorder, Schizophrenia and Disorders With Psychotic Feature
Building a Computational Model of Auditory Hallucinations
Some people hear voices or sounds that other people cannot hear; these are called auditory hallucinations. The study aims to understand what is happening in the brain when this occurs and will use brain scans to learn more.
- Conditions
- Schizophrenia / Schizoaffective Disorder, Schizophrenia and Disorders With Psychotic Feature, Psychosis, SCHIZOPHRENIA 1 (Disorder)
- Trial name
- CLARITY WP1 (NCT07820553)
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- King's College London
Schizophrenia / Schizoaffective Disorder, TMS
Efficacy and Safety of Individualized Sequential Accelerated Theta Burst Stimulation in Improving Cognitive Function in Schizophrenia
The goal of this clinical trial is to learn if sequential dual-site accelerated theta burst stimulation (SD-aTBS) targeting the frontoparietal network and default mode network works to improve cognitive function in adults with…
- Conditions
- Schizophrenia / Schizoaffective Disorder, TMS, Cognitive, PET / MR
- Trial name
- NCT07806877
- Testing
- Sequential Dual-Site Accelerated Theta Burst Stimulation (SD-aTBS)
- Volunteers
- 60 people
- Sponsor
- Central South University
Schizophrenia, Schizoaffective Disorder
Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia
Plasma half-life has routinely been used to establish the dosing schedule of antipsychotics; for example, it is recommended that agents with a short plasma half-life be administered multiple times per day.
- Trial name
- NCT02639702
- Testing
- Clozapine
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder
Cerebellar Modulation of Cognition in Psychosis
The goal of this clinical trial is to learn about cognition in psychotic disorders (schizophrenia, bipolar disorder, and schizoaffective disorder).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder I, Psychosis
- Trial name
- NCT06107764
- Testing
- intermittant theta burst stimulation (iTBS), continuous theta burst stimulation (cTBS)
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Mclean Hospital
Schizophrenia, Schizoaffective Disorder
Enhancing Veteran-Clinical Collaboration in VA PRRCs
Over 60% of Veterans with serious mental illness have a service-connected disability that impairs their ability to work, go to school, and/or have successful personal lives.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder, Bipolar Disorder
- Trial name
- EVCC VPRRC (NCT06898879)
- Testing
- Collaborative Decision Skills Training, Leveling Up
- Where
- 3 sites in United States
- Volunteers
- 119 people
- Sponsor
- VA Office of Research and Development
Schizophrenia and Schizoaffective Disorder
A Trial of Group Cognitive Behavioral Therapy for Psychosis (the Feeling Safe Programme)
Schizophrenia is a serious psychiatric disorder characterized by delusions, hallucinations, negative symptoms and disorganized behaviour.
- Trial name
- NCT07408934
- Testing
- Cognitive Behavioral Therapy for Psychosis
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Schizophrenia, Schizophreniform Disorder
Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode
The participants in the study will receive psychiatric treatment at the UCLA Aftercare Research Program. All participants in this 12-month RCT will receive cognitive training.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- NCT05890183
- Testing
- Cognitive training, Aerobic Exercise Program, Moderated Online Social Therapy (MOST)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, Los Angeles
Psychosis, Schizophrenia Disorder
Cognitive Strategies in Early Psychosis 2
The goal of this clinical trial is to learn more about decision making in psychosis spectrum disorders, like schizophrenia. Participants will be people who have had symptoms of a psychosis spectrum disorder start within the last…
- Conditions
- Psychosis, Schizophrenia Disorder, Schizoaffective Disorder, Major Depressive Disorder With Psychotic Features
- Trial name
- COSTEP 2 (NCT07263022)
- Testing
- Modafinil, D-serine solution
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Minnesota
Schizoaffective Disorders, Bipolar Disorder With Psychotic Features
Transition Care for FEP
This study is testing a new approach to help people with first episode psychosis transition successfully from the hospital to outpatient mental health care.
- Conditions
- Schizoaffective Disorders, Bipolar Disorder With Psychotic Features, Schizophrenia Disorders, Major Depressive Disorder With Psychotic Features
- Trial name
- TCT FEP (NCT07713849)
- Testing
- Transition Care Team
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- University of Chicago
Schizoaffective Disorder, Schizophreniform Disorder
Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in Schizophrenia
This is a clinical trial in which 40 participants with schizophrenia will be randomized to 15 days of treatment with cariprazine (CAR) or brexpiprazole (BREX) in a single-blind manner.
- Conditions
- Schizoaffective Disorder, Schizophreniform Disorder, Schizophrenia
- Trial name
- NCT07715253
- Testing
- Brexpiprazole, Cariprazine, [11C] PHNO
- Volunteers
- 100 people
- Sponsor
- New York State Psychiatric Institute